The Role of CD34 and D2-40 in the Differentiation of Dermatofibroma and Dermatofibrosarcoma Protuberans

Creative Commons License

Sadullahoglu C., Dere Y., Rezanko Atasever T., Tunakan Oztop M., Karaaslan O.

TURKISH JOURNAL OF PATHOLOGY, vol.33, no.3, pp.223-227, 2017 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 33 Issue: 3
  • Publication Date: 2017
  • Doi Number: 10.5146/tjpath.2017.01402
  • Journal Name: TURKISH JOURNAL OF PATHOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.223-227
  • Keywords: Dermatofibroma, Dermatofibrosarcoma protuberans, CD34, D2-40, Podoplanin, PODOPLANIN, EXPRESSION, TUMORS, IMMUNOREACTIVITY, BENIGN
  • Akdeniz University Affiliated: Yes

Abstract

Objective: Dermatofibroma (DF) is a benign fibrohistiocytic tumor whereas dermatofibrosarcoma protuberans (DFSP) has intermediate malignant potential. CD34 is the most commonly used antibody in differentiating these tumors. Various studies have stated the rates of D2-40 expression as 0-50% in DFSPs and 86-100% in DFs. Our aim in this study was to determine the expression of CD34 and D2-40 in DFs and DFSPs and the possible use of D2-40 in the differential diagnosis of these lesions.